<DOC>
	<DOC>NCT01392716</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of MabThera/Rituxan (rituximab) in treatment-naive patients with non-bulky follicular non-Hodgkin`s lymphoma. The anticipated time on study treatment is 3 months.</brief_summary>
	<brief_title>A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patients 1875 years of age Newly diagnosed nonbulky follicular nonHodgkin's lymphoma &gt;/=1 measurable lesion No prior treatment (no corticosteroids or radiotherapy) Transformed follicular lymphoma Cerebral or meningeal lymphomaotus localization Uncontrolled concurrent infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>